These are slides of the survey results from 4 weekly surveys conducted in September 2023 – during the “Hard Decisions in RA” Campaign Each Survey week had a different theme: Oral Surveillance Revisited Early RA Methotrexate Decisions DMARD Chices & Changes Thanks to BMS for sponsoring this campaign on “Hard Decisions in RA”

How best do we communicate CV risk associated with RA to other members of the treating team, most particularly the primary care physicians (known as ‘General Practitioners’ here in Australia)? After some experimentation, I have come up with an approach that seems to work and which does not take up much time.

This Tuesday Night Rheumatology panel discusses “DMARD Choices & Changes”, including weaning, biosimilars, and guideline views from a panel that includes Drs. Madelaine Feldman, Alan Matsumoto, Artie Kavanaugh and Jack Cush. Recorded on 9/16/2023 Disclosures The author has no conflicts of interest to disclose related to this subject …

In June 2023, RheumNow surveyed US and non-US rheumatologists (Rheums) about how they consider and manage pre-clinical rheumatoid arthritis (RA) in their practice.  In the last few years there have been numerous well designed and appropriately powered randomized clinical trials of pre-clinical RA patients receiving either a placebo or active intervention.  Such trials of common or targeted therapies studies named PRAIRI (rituximab), TREAT-EARLIER (methotrexate), STOP-RA (hydroxychloroquine), ARIAA and APIPPRA (both with abatacept).

Drs. Iain McInnes and Gerd Burmester discuss their perspectives on the future management of people with RA. These and more debates and perspectives on Hard Decisions in RA now available.